Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | GABRR1 | P24046 | 5/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.37 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | PEPD | P12955 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241114 | 1.00 | EPHX1 (0.45) | EPHX1GABRR1SLC1A2SLC1A1GABRR2 | |
| SCHEMBL9805204 | 1.00 | EPHX1 (0.45) | EPHX1GABRR1SLC1A2SLC1A1GABRR2 | |
| SCHEMBL23645186 | 0.97 | EPHX1 (0.44) | EPHX1GABRR1SLC1A2SLC1A1GABRR2 | |
| SCHEMBL29282863 | 0.97 | EPHX1 (0.44) | EPHX1GABRR1SLC1A2SLC1A1GABRR2 | |
| SCHEMBL29282879 | 0.97 | EPHX1 (0.44) | EPHX1GABRR1SLC1A2SLC1A1GABRR2 | |
| SCHEMBL23645184 | 0.97 | EPHX1 (0.44) | EPHX1GABRR1SLC1A2SLC1A1GABRR2 | |
| SCHEMBL30922216 | 0.97 | EPHX1 (0.44) | EPHX1GABRR1SLC1A2SLC1A1GABRR2 | |
| SCHEMBL23645188 | 0.97 | EPHX1 (0.44) | EPHX1GABRR1SLC1A2SLC1A1GABRR2 | |
| SCHEMBL9065278 | 0.93 | EPHX1 (0.41) | EPHX1PEPD | |
| SCHEMBL17657326 | 0.88 | EPHX1 (0.41) | EPHX1GABRR1SLC1A2SLC1A1GABRR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | EPHX1 262/4885GABRR1 145/4885SLC1A2 1570/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | EPHX1 277/4885GABRR1 149/4885SLC1A2 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.